Stocktoria
Innoviva, Inc. INVA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-10-05
Innoviva, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $411.3M | $358.7M | $310.5M | $331.3M | $391.9M |
| Gross profit | $307.7M | $296.2M | $246.0M | — | — |
| R&D expense | $30.6M | $13.7M | $33.9M | $41.4M | $576,000 |
| SG&A expense | $113.3M | $115.7M | $98.2M | $63.5M | $16.2M |
| Operating income | $163.7M | $166.9M | $113.9M | — | $375.1M |
| Interest expense | $16.7M | $22.2M | $19.2M | $15.8M | $19.1M |
| Income tax | $55.7M | $14.0M | $14.4M | $66.7M | $76.4M |
| Operating cash flow | $196.9M | $188.7M | $141.1M | $201.7M | $363.8M |
| Free cash flow | $195.8M | $188.4M | $140.7M | $201.7M | $363.8M |
| Cash & equivalents | $550.9M | $305.0M | $193.5M | $291.0M | $201.5M |
| Inventory | $39.2M | $33.7M | $40.7M | $55.9M | $0 |
| Total assets | $1.6B | $1.3B | $1.2B | $1.2B | $926.4M |
| Shareholders' equity | $1.2B | $691.2M | $675.0M | $565.8M | $525.9M |
| EPS (diluted) | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 |
Source: SEC EDGAR filings · CIK 0001080014 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.